The size of oligonucleotides lies between that of small, low-molecular-weight active pharmaceutical ingredients (APIs) and high-molecular-weight active pharmaceutical ingredients such as mAbs (monoclonal antibodies). Production facilities for the manufacture of oligonucleotides must be able to handle flammable, toxic compounds as well as meet hygienic standards to ensure biological integrity. Above all, however, they must be flexible and able to be scaled up from pilot plants so that they can ideally synthesize and purify a wide variety of drugs.

The post Diaphragm Metering Pumps Prove Their Worth for Critical Mixing Tasks in Industrial Oligonucleotide Production appeared first on Fluid Handling Pro.